Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus

Clinical Chemistry

Volumn 51, Issue 8, 2005, Pages 1374-1381

  Kamdem, Landry K ^a   Streit, Frank ^a   Zanger, Ulrich M ^b   Brockmöller, Jürgen ^a   Oellerich, Michael ^a   Armstrong, Victor W ^a   Wojnowski, Leszek ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

13 O NORTACROLIMUS; COMPLEMENTARY DNA; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DRUG METABOLITE; RECOMBINANT ENZYME; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CATALYSIS; DEMETHYLATION; DOSE RESPONSE; DRUG CLEARANCE; ENZYME ACTIVITY; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CLEARANCE; LIVER MICROSOME; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; TANDEM MASS SPECTROMETRY;

BACULOVIRIDAE; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROSOMES, LIVER; TACROLIMUS;

EID: 23044476217     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.050047     Document Type: Article

References (49)

1. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987;19:4-8.
2. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002;41:813-51.
3. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998;31:309-16.
4. Christians U, Kruse C, Kownatzki R, Schiebel HM, Schwinzer R, Sattler M, et al. Measurement of FK 506 by HPLC and isolation and characterization of its metabolites. Transplant Proc 1991;23: 940-1.
5. Lhoest G, Wallemacq P, Verbeeck R. Isolation and mass spectrometric identification of five metabolites of FK-506, a novel macrolide immunosuppressive agent, from human plasma. Pharm Acta Helv 1991;66:302-6.
6. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
7. Vincent SH, Karanam BV, Painter SK, Chiu SH. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992;294:454-60.
8. Lhoest GJ, Maton N, Latinne D, Laurent A, Verbeeck RK. 15-Desmethyl FK-506 and 15,31-desmethyl FK-506 from human liver microsomes: isolation, identification (by fast atom bombardment mass spectrometry and NMR), and evaluation of in vitro immunosuppressive activity. Clin Chem 1994;40:740-4.
9. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994;47:727-35.
10. Karanam BV, Vincent SH, Newton DJ, Wang RW, Chiu SH. FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab Dispos 1994;22:811-4.
11. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-24.
12. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9.
13. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
14. Haufroid V, Mourad M, Van Kerchkove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004;14:147-54.
15. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002;74:1486-9.
16. Hesselink DA, van Schaik RH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54.
17. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus closes and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003;76:1233-5.
18. Zheng H, Webber S, Zetivi A, Schuetz E, Zhang J, Bowman P, ,et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant 2003;3:477-83.
19. Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 2004;44:135-40.
20. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005;6:37-47.
21. Macphee IA, Fredericks S, Mohamed M, Moreton M, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005;79:499-502.
22. Thummel KE. A genetic test for immunosuppressant dose selection? Pharmacogenetics 2004;14:145-6.
23. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004;4:914-9.
24. Burk O, Koch I, Raucy J, Mustert E, Eichelbaum M, Brockmoller J, et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004;279:38379-85.
25. Bader A, Hansen T, Kirchner G, Allmeling C, Haverich A, Borlak JT. Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 2000;129:331-42.
26. Evert B, Eichelbaum M, Haubruck H, Zanger UM. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn Schmiedebergs Arch Pharmacol 1997;355:309-18.
27. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 2000;28:1493-504.
28. Houston JB, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994;47:1469-79.
29. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 2001;297:326-37.
30. Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 1999;47:625-35.
31. Iwasaki K, Miyazaki Y, Teramura Y, Kawamura A, Tozuka Z, Hata T, et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. Res Commun Mol Pathol Pharmacol 1996;94:251-7.
32. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283:46-58.
33. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350-9.
34. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred "model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977;5:625-53.
35. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90.
36. Kamdem LK, Meineke I, Koch I, Zanger UM, Brockmoller J, Wojnowski L. Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol 2004;370:71-7.
37. Gillam EM, Quo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, et al. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 1995;317:374-84.
38. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004;32:1434-45.
39. Klees TM, Sheffels P, Dale O, Kharasch ED. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos 2005;33:303-11.
40. Burk O, Tegude H, Koch I, Mustert E, Wolbold R, Glaeser H, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 2002;277: 24280-8.
41. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, et al. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese s. Drug Metab Pharmacokinet 2004;19:120-9.
42. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab - Dispos 2002;30:1311-9.
43. I values and impact of CYP3A5 expression. Drug Metab Dispos 1999;27:180-7.
44. Khan KK, He YQ, Correia MA, Halpert JR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos 2002;30:985-90.
45. Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004;78:1182-7.
46. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation, Pharmacogenetics 2004;14:471-8.
47. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin, J Biol Chem 2001;276:14581-7.
48. Katz DA, Grimm DR, Cassar SC, Gentile MC, Ye X, Rieser MJ, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther 2004;75:516-28.
49. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14:523-5.